The feared “patent cliff” for brand-name drugs, which has caused billion-dollar blockbusters like Pfizer’s Lipitor and Bristol-Myers Squibb’s Plavix to lose ground to generic competition, has been driving Big Pharma to hunt for innovation among small biotechs, the New York Times reports.